Literature DB >> 9668050

Substrate specificity of heparanases from human hepatoma and platelets.

D S Pikas1, J P Li, I Vlodavsky, U Lindahl.   

Abstract

Heparan sulfate proteoglycans, attached to cell surfaces or in the extracellular matrix, interact with a multitude of proteins via their heparan sulfate side chains. Degradation of these chains by limited (endoglycosidic) heparanase cleavage is believed to affect a variety of biological processes. Although the occurrence of heparanase activity in mammalian tissues has been recognized for many years, the molecular characteristics and substrate recognition properties of the enzyme(s) have remained elusive. In the present study, the substrate specificity and cleavage site of heparanase from human hepatoma and platelets were investigated. Both enzyme preparations were found to cleave the single beta-D-glucuronidic linkage of a heparin octasaccharide. A capsular polysaccharide from Escherichia coli K5, with the same (-GlcUAbeta1,4-GlcNAcalpha1,4-)n structure as the unmodified backbone of heparan sulfate, resisted heparanase degradation in its native state as well as after chemical N-deacetylation/N-sulfation or partial enzymatic C-5 epimerization of beta-D-GlcUA to alpha-L-IdceA. By contrast, a chemically O-sulfated (but still N-acetylated) K5 derivative was susceptible to heparanase cleavage. O-Sulfate groups, but not N-sulfate or IdceA residues, thus are essential for substrate recognition by the heparanase(s). In particular, selective O-desulfation of the heparin octasaccharide implicated a 2-O-sulfate group on a hexuronic acid residue located two monosaccharide units from the cleavage site, toward the reducing end.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9668050     DOI: 10.1074/jbc.273.30.18770

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  63 in total

1.  Characterization of a novel intracellular heparanase that has a FERM domain.

Authors:  Karen J Bame; Indumati Venkatesan; Jean Dehdashti; Jeffrey McFarlane; Rebecca Burfeind
Journal:  Biochem J       Date:  2002-05-15       Impact factor: 3.857

Review 2.  Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis.

Authors:  I Vlodavsky; Y Friedmann
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

3.  Expression of heparanase in normal, dysplastic, and neoplastic human colonic mucosa and stroma. Evidence for its role in colonic tumorigenesis.

Authors:  Y Friedmann; I Vlodavsky; H Aingorn; A Aviv; T Peretz; I Pecker; O Pappo
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

4.  Temporal and functional changes in glycosaminoglycan expression during osteogenesis.

Authors:  Victor Nurcombe; Fuqi Jack Goh; Larisa M Haupt; Sadasivam Murali; Simon M Cool
Journal:  J Mol Histol       Date:  2007-08-03       Impact factor: 2.611

Review 5.  Molecular engineering of glycosaminoglycan chemistry for biomolecule delivery.

Authors:  Tobias Miller; Melissa C Goude; Todd C McDevitt; Johnna S Temenoff
Journal:  Acta Biomater       Date:  2013-10-09       Impact factor: 8.947

6.  Evidence that platelet and tumour heparanases are similar enzymes.

Authors:  C Freeman; A M Browne; C R Parish
Journal:  Biochem J       Date:  1999-09-01       Impact factor: 3.857

Review 7.  Soluble syndecans: biomarkers for diseases and therapeutic options.

Authors:  Jessica Bertrand; Miriam Bollmann
Journal:  Br J Pharmacol       Date:  2018-07-23       Impact factor: 8.739

Review 8.  Non-anticoagulant heparins and inhibition of cancer.

Authors:  Benito Casu; Israel Vlodavsky; Ralph D Sanderson
Journal:  Pathophysiol Haemost Thromb       Date:  2009-01-27

Review 9.  Versatile role of heparanase in inflammation.

Authors:  Rachel Goldberg; Amichay Meirovitz; Nir Hirshoren; Raanan Bulvik; Adi Binder; Ariel M Rubinstein; Michael Elkin
Journal:  Matrix Biol       Date:  2013-03-13       Impact factor: 11.583

Review 10.  Heparanase and hepatocellular carcinoma: promoter or inhibitor?

Authors:  Shuo Dong; Xiong-Zhi Wu
Journal:  World J Gastroenterol       Date:  2010-01-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.